Efficient mRNA-based genetic engineering of human NK cells with high-affinity CD16 and CCR7 augments rituximab-induced ADCC against lymphoma and targets NK cell migration toward the lymph node-associated chemokine CCL19

Frontiers in Immunology

Volumn 7, Issue MAR, 2016, Pages

  Carlsten, Mattias ^a   Levy, Emily ^a   Karambelkar, Amrita ^a   Li, Linhong ^b   Reger, Robert ^a   Berg, Maria ^a   Peshwa, Madhusudan V ^b   Childs, Richard W ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b MAXCYTE INC   (United States)

Author keywords

Antibody dependent cellular cytotoxicity; Cellular migration; Gene therapy; NK cell immunotherapy; NK cells

Indexed keywords

CD16 ANTIGEN; CD34 ANTIGEN; CHEMOKINE RECEPTOR CCR7; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MESSENGER RNA; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; RITUXIMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL MIGRATION; CELL MIGRATION ASSAY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DEGRANULATION; ELECTROPORATION; FLOW CYTOMETRY; GENETIC ENGINEERING; HUMAN; HUMAN CELL; LYMPHOMA; NATURAL KILLER CELL;

EID: 84964692705     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00105     Document Type: Article

References (17)

1. Miller JS, Soignier Y, Panoskaltsis-Mortari A, Mcnearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 105:3051-7. doi:10.1182/blood-2004-07-2974.
2. Li L, Liu LN, Feller S, Allen C, Shivakumar R, Fratantoni J, et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther (2010) 17:147-54. doi:10.1038/cgt.2009.61.
3. Childs RW, Berg M. Bringing natural killer cells to the clinic: ex vivo manipulation. Hematology Am Soc Hematol Educ Program (2013) 2013:234-46. doi:10.1182/asheducation-2013.1.234.
4. Childs RW, Carlsten M. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov (2015) 14:487-98. doi:10.1038/nrd4506.
5. Carlsten M, Childs RW. Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications. Front Immunol (2015) 6:266. doi:10.3389/fimmu.2015.00266.
6. Shimasaki N, Fujisaki H, Cho D, Masselli M, Lockey T, Eldridge P, et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy (2012) 14:830-40. doi:10.3109/14653249.2012.671519.
7. Byers MA, Calloway PA, Shannon L, Cunningham HD, Smith S, Li F, et al. Arrestin 3 mediates endocytosis of CCR7 following ligation of CCL19 but not CCL21. J Immunol (2008) 181:4723-32. doi:10.4049/jimmunol.181.7.4723.
8. Dannull J, Haley NR, Archer G, Nair S, Boczkowski D, Harper M, et al. Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest (2013) 123:3135-45. doi:10.1172/JCI67544.
9. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res (2014) 2:112-20. doi:10.1158/2326-6066.CIR-13-0170.
10. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 18:843-51. doi:10.1038/mt.2010.24.
11. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 6:224ra225. doi:10.1126/scitranslmed.3008226.
12. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 257:107-26. doi:10.1111/imr.12131.
13. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest (1997) 100:1059-70. doi:10.1172/JCI119616.
14. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol (2003) 21:3940-7. doi:10.1200/JCO.2003.05.013.
15. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol (2005) 23:474-81. doi:10.1200/JCO.2005.06.059.
16. Pander J, Gelderblom H, Antonini NF, Tol J, Van Krieken JH, Van Der Straaten T, et al. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer (2010) 46:1829-34. doi:10.1016/j.ejca.2010.03.017.
17. Somanchi SS, Somanchi A, Cooper LJ, Lee DA. Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood (2012) 119:5164-72. doi:10.1182/blood-2011-11-389924.